MedX Health Corp. (TSX-V:MDX) and Vitamed Biomedical s.r.l. have announced a memorandum of understanding (MOU) to pilot MedX’s leading-edge DermSecure Screening Platform at select pharmacies and general practitioner (GP) clinics in Italy.
In a statement, MedX said the pilot program is expected to be in-market for 60 days from October to November 2021.
Pending its successful completion, the MedX DermSecure Screening Platform will become more widely available at pharmacies, GP clinics, and insurance companies across Italy, as the next step in the commercialization strategy in this market.
READ: MedX Health generates revenue in 2Q and expects ‘increasing activity’ during the year
MedX said it will continue to build on this momentum with additional pilots anticipated later in 2021.
Europe continues to be a strong focus of MedX’s global commercialization strategy, following the ongoing success of its pilot program in the Netherlands.
“I’m really excited to start this partnership program with MedX in Italy,” said Giuseppe Verderame, founder and CEO of Vitamed. “We are very confident that teledermatology will be able to offer great opportunities to support Dermatologists, Physicians and the Healthcare System for the benefit of patient wellbeing.”
Unlike other teledermatology screening tools available, MedX’s platform features high-resolution image capture technology for moles, lesions, and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions, and other skin conditions via its image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
“Thanks to the virtual nature of our teledermatology platform and the precision of our SIAscopy technology, our product offering is uniquely positioned to fulfill the global need for accessible, efficient healthcare services – particularly amid the ongoing COVID-19 pandemic,” said Sylvain Desjeans, who was recently appointed CEO of MedX.
“This is a time of rapid growth for MedX, with two pilots now being offered in Europe and additional pilot opportunities on the horizon. Working closely with Vitamed will allow us to make a measurable difference in the European market – improving patient outcomes and potentially saving lives around the world.”
According to the World Cancer Research Fund, Italy has the 19th highest rate of skin cancer in the world. The World Health Organization’s International Agency for Research on Cancer estimated that 12,515 Italians were diagnosed with melanoma skin cancer in 2020, with approximately 2,224 Italians dying of the disease. Early and rapid detection of melanoma is key to improving patient outcomes.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham